Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus is a PHASE3 clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: semaglutide, liraglutide, placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.